Identifies themes and clusters of stock movements
Market TodayThemes and Stocks AnalysesThematic Stock SearchClick here for daily refresh schedule
MGTX - MeiraGTx Holdings Plc
$12.66
-0.05(-0.39%)9:00:00 PM 11/23/2020
MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    11/23/2020MGTX
    MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

    LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The virtual conference will be held from December 1-3, 2020. The pre-recorded fireside chat is currently available on the Investors page of the Company’s webs...

    11/19/2020MGTX
    Why MeiraGTx Holdings Stock Is Down Today

    Shares of MeiraGTx Holdings (NASDAQ:MGTX) -- a clinical-stage biotech company -- are down by 11.51% as of 11:55 a.m. EST on Thursday, following the company's announcement of the pricing of a public offering of common stock. The company will sell 5 million ordinary shares through an underwritten public offering at a price of $12.85 per share. As of this writing, the company's stock is down to $12.83, which is more or less in line with the public offering price.

    11/19/2020MGTX
    MeiraGTx Announces Pricing of Public Offering of Ordinary Shares

    LONDON and NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 of its ordinary shares at a public offering price of $12.85 per share. In addition, MeiraGTx has granted the underwriters a 30-day option to purchase up to an additional 750,000 of its ordinary shares at the public offering price, less underwriting discounts and commiss...

    11/18/2020MGTX
    MeiraGTx Announces Proposed Public Offering of Ordinary Shares

    LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of 5,000,000 of its ordinary shares. In connection with the offering, MeiraGTx intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 of its ordinary shares. All of the ordinary shares are being offered by MeiraGTx. BofA Securities, Piper S...

    11/13/2020MGTX
    MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment

    Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 monthsLONDON and NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP). Statistically significant v...

    11/10/2020MGTX
    MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit

    LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Monday, November 16, 2020 at 1:30 p.m. ET. A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the w...

    11/10/2020MGTX
    Upgrade: Analysts Just Made A Huge Increase To Their MeiraGTx Holdings plc (NASDAQ:MGTX) Forecasts

    Shareholders in MeiraGTx Holdings plc (NASDAQ:MGTX) may be thrilled to learn that the analysts have just delivered a...